Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -107.01% is 60% above its 5-year average of -268.38%, near the high end of its 5-year range (-4774.10%–76.11%).
92.07% above its 12-month average of -1349.14%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -841.57%.
EBITDA MARGIN
-107.01%
EBITDA MARGIN AVG TTM
-1349.14%
EBITDA MARGIN AVG 3Y
-247.73%
EBITDA MARGIN AVG 5Y
-268.38%
EBITDA MARGIN AVG 10Y
-285.20%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+92.07%
CURRENT VS 3Y AVG
+56.80%
CURRENT VS 5Y AVG
+60.13%
CURRENT VS 10Y AVG
+62.48%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Arcturus Therapeutics Holdings Inc.
Market Cap
$398.49M
EBITDA Margin
-107.01%
TTM Avg
-1349.14%
3Y Avg
-247.73%
5Y Avg
-268.38%
Market Cap
$389.14M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$408.54M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$411.45M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$412.14M
EBITDA Margin
39.39%
TTM Avg
8.38%
3Y Avg
8.38%
5Y Avg
8.38%
Market Cap
$412.76M
EBITDA Margin
-59.97%
TTM Avg
-74.12%
3Y Avg
-94.06%
5Y Avg
-94.06%
Market Cap
$378.75M
EBITDA Margin
-403.32%
TTM Avg
-429.38%
3Y Avg
-429.38%
5Y Avg
-429.38%
Market Cap
$376.18M
EBITDA Margin
-12.87%
TTM Avg
-20.20%
3Y Avg
-216.20%
5Y Avg
-209.97%
Market Cap
$432.00M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $398.49M | -107.01% | -1349.14% | -247.73% | -268.38% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $389.14M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $408.54M | -48.80% | -44.09% | -45.35% | -45.35% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $411.45M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | 39.39% | 8.38% | 8.38% | 8.38% |
| Carlsmed, Inc. (CARL)vs › | $412.76M | -59.97% | -74.12% | -94.06% | -94.06% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $378.75M | -403.32% | -429.38% | -429.38% | -429.38% |
| Canopy Growth Corporation (CGC)vs › | $376.18M | -12.87% | -20.20% | -216.20% | -209.97% |
| Editas Medicine, Inc. (EDIT)vs › | $432.00M | -232.13% | -495.69% | -578.57% | -532.48% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $434.84M | -184.73% | -138.06% | -2467.18% | -2497.88% |
Gross Margin
95.5%
EBITDA Margin
-107.0%
Operating Margin
-111.5%
Net Margin
-391.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -841.57% |
| 2026-03-31 | -4774.10% |
| 2025-12-31 | -994.00% |
| 2025-09-30 | -91.83% |
| 2025-06-30 | -44.21% |
| 2025-03-31 | -54.54% |
| 2024-12-31 | -155.12% |
| 2024-09-30 | -25.31% |
| 2024-06-30 | -43.97% |
| 2024-03-31 | -90.52% |
| 2023-12-31 | -69.61% |
| 2023-09-30 | -42.62% |
| 2023-06-30 | -519.41% |
| 2023-03-31 | 19.10% |
| 2022-12-31 | 76.11% |
| 2022-09-30 | -272.20% |
| 2022-06-30 | -80.29% |
| 2022-03-31 | -956.43% |
| 2021-12-31 | -644.37% |
| 2021-09-30 | -2196.64% |
| 2021-06-30 | -2670.31% |
| 2021-03-31 | -2696.71% |
| 2020-12-31 | -1376.81% |
| 2020-09-30 | -888.08% |
| 2020-06-30 | -423.34% |
| 2020-03-31 | -350.72% |
| 2019-12-31 | -359.30% |
| 2019-09-30 | -218.47% |
| 2019-06-30 | -0.35% |
| 2019-03-31 | -145.66% |
| 2018-12-31 | -7.18% |
| 2018-09-30 | -122.61% |
| 2018-06-30 | -416.05% |
| 2018-03-31 | -277.19% |
| 2017-12-31 | 1.45% |
| 2017-09-30 | -86.50% |
| 2017-06-30 | -101.25% |
| 2017-03-31 | -94.01% |
